G6PD and head and neck cancer: Taken together, these data support the potential for use of the NRF2/G6PD/TKT gene signature as a prognostic biomarker and for the development of NRF2-targeted therapies that alter cellular metabolism as novel and promising treatment options for head and neck cancer.